-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Multidisciplinary Discussion on Incorporating IMBRUVICA® (ibrutinib) Into Treatment Strategies

Sponsor: Pharmacyclics LLC and Janssen Biotech, Inc.
Program: Product Theaters
Monday, December 12, 2022: 8:00 AM-9:00 AM
Hall J - Theater 7 (Ernest N. Morial Convention Center)
James P. Dean, MD, PhD, Pharmacyclics LLC , Christopher Campen, PharmD, Janssen Biotech, Inc. and Sandra Knight, MN, BC-APN, CNS, AOCN, Pharmacyclics LLC
No relevant conflicts of interest to declare.
For in-person participants only
See more of: Product Theaters